ZB
CRL icon

Zions Bancorporation’s Charles River Laboratories CRL Stock Holding History

Zions Bancorporation’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.87M Buy
10,121
+1,594
+19% +$307K 0.12% 160
2024
Q3 		$1.68M Buy
8,527
+1,275
+18% +$265K 0.12% 151
2024
Q2 		$1.5M Sell
7,252
-234
-3% -$53K 0.12% 135
2024
Q1 		$2.03M Buy
7,486
+303
+4% +$72.4K 0.15% 117
2023
Q4 		$1.7M Buy
7,183
+456
+7% +$89.7K 0.12% 138
2023
Q3 		$1.32M Buy
6,727
+1,473
+28% +$302K 0.12% 141
2023
Q2 		$1.1M Buy
5,254
+294
+6% +$58.5K 0.09% 170
2023
Q1 		$1M Buy
4,960
+574
+13% +$130K 0.09% 191
2022
Q4 		$956K Buy
4,386
+1,847
+73% +$403K 0.08% 174
2022
Q3 		$500K Buy
2,539
+2,536
+84,533% +$547K 0.05% 229
2022
Q2 		$1K Sell
3
-3
-50% -$733 ﹤0.01% 1011
2022
Q1 		$2K Sell
6
-88
-94% -$27.1K ﹤0.01% 1046
2021
Q4 		$35K Buy
94
+4
+4% +$1.55K ﹤0.01% 514
2021
Q3 		$37K Sell
90
-2,385
-96% -$991K ﹤0.01% 488
2021
Q2 		$916K Buy
2,475
+295
+14% +$98.5K 0.09% 117
2021
Q1 		$632K Sell
2,180
-14
-0.6% -$3.89K 0.07% 128
2020
Q4 		$548K Buy
2,194
+67
+3% +$16K 0.07% 115
2020
Q3 		$482K Sell
2,127
-87
-4% -$18.1K 0.07% 115
2020
Q2 		$386K Buy
2,214
+189
+9% +$30.2K 0.06% 131
2020
Q1 		$256K Buy
2,025
+177
+10% +$26.5K 0.04% 140
2019
Q4 		$282K Sell
1,848
-469
-20% -$64.9K 0.04% 155
2019
Q3 		$307K Sell
2,317
-104
-4% -$13.9K 0.04% 164
2019
Q2 		$344K Buy
2,421
+124
+5% +$16.8K 0.05% 137
2019
Q1 		$334K Buy
+2,297
New +$302K 0.05% 138
2018
Q2 		– Sell
-2,105
Closed -$225K – 497
2018
Q1 		$225K Buy
2,105
+160
+8% +$17.2K 0.05% 120
2017
Q4 		$213K Sell
1,945
-20
-1% -$2.18K 0.04% 151
2017
Q3 		$212K Buy
+1,965
New +$202K 0.03% 251
2016
Q3 		– Sell
-1
Closed – – 839
2016
Q2 		$0 Buy
+1
New +$82 ﹤0.01% 839

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

Zions Bancorporation's CRL Position: Q4 2024 in Review

Zions Bancorporation increased its Charles River Laboratories (CRL) stake by 19% in Q4 2024, buying an estimated $307K and bringing the position to 10,121 shares worth $1.87M. The position accounts for 0.12% of the portfolio, ranked #160.

Zions Bancorporation first reported a position in CRL in Q2 2016 and has held it in 28 quarters since. The position peaked at $2.03M in Q1 2024. 636 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

  • Zions Bancorporation held 10,121 shares of Charles River Laboratories worth $1.87M as of Q4 2024.
  • Zions Bancorporation bought 1,594 Charles River Laboratories shares in Q4 2024, an estimated $307K.
  • Charles River Laboratories made up 0.12% of Zions Bancorporation's portfolio in Q4 2024, its #160 holding.
  • Zions Bancorporation first reported a position in Charles River Laboratories in Q2 2016 and has held it in 28 quarters since.
  • Zions Bancorporation's Charles River Laboratories position peaked at $2.03M in Q1 2024.
  • 636 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.